FOR IMMEDIATE RELEASE

Bonti Announces Poster Presentation on EB-001 Pharmacological Profile at Abdominal Wall Reconstruction Conference

Lead Product Candidate, A Botulinum Neurotoxin Serotype E (BoNT/E), To Be Featured on June 8th in Washington, DC

NEWPORT BEACH, CA, USA – June 6, 2017 – Bonti, a privately-held, clinical-stage biotechnology company, today announced a poster presentation highlighting the pharmacological profile of its lead molecule, EB-001, a fast-acting botulinum neurotoxin. The poster at the 2017 Abdominal Wall Reconstruction (AWR) Conference, hosted by MedStar Georgetown University Hospital, will show the pharmacological efficacy of EB-001 compared to BOTOX® (BoNT/A) in a mouse Digit Abduction Score (DAS) assay. EB-001 is a novel neurotoxin with a unique target profile, characterized by fast onset of action and short duration of effect. The clinical safety and efficacy of EB-001 is being investigated in Phase 2 trials for therapeutic and aesthetic uses. EB-001 target indications will address areas of unmet medical needs, where the molecule’s product profile is highly beneficial, with multi-billion dollar total addressable market opportunities.

The poster spotlights the DAS assay, a well-established in vivo model used to assess muscle-relaxing effects of botulinum neurotoxin preparations, including onset of action and duration of effect. The EB-001 and BOTOX mice test groups demonstrated dose-dependent muscle relaxation as measured by DAS, with two major differences. The poster concludes that, in the DAS model, EB-001 has a faster onset and a more limited duration of effect compared to BOTOX, which may support EB-001’s clinical utility in procedures such as abdominoplasties.

The DAS data supports the EB-001 target clinical profile (fast onset, short duration) and provides a strong foundation for EB-001 clinical studies in a wide variety of musculoskeletal conditions. A fast onset, limited duration neurotoxin could prove beneficial for effective muscle relaxation, relief of tension and opioid-sparing treatment of musculoskeletal pain following AWR procedures. Based on non-clinical studies to date, the target clinical profile is:

- Fast onset of action for EB-001: About 24 hours; current BoNT/As have an onset of action around 3 – 7 days
Short duration of effect for EB-001: About 4 weeks; current BoNT/As have a duration of effect around 3 – 4 months

“All of us at Bonti are thrilled to highlight EB-001’s unique pharmacological profile and animal efficacy via this poster at the upcoming conference,” commented Fauad Hasan, co-founder and CEO of Bonti. “It is an honor to share our findings with the AWR Conference attendees and we are grateful to the organizers for accepting our poster. We realize BOTOX has been used in AWR procedures to reduce post-operative pain and incisional tension though its utility is limited by delayed onset of effect and long duration. So, a fast-acting, short duration neurotoxin like EB-001 could offer clinical benefits in treating post-operative musculoskeletal pain and the shorter duration of muscle weakness may support recovery and rehabilitation following AWR procedures.”

“Reflecting on surgeries in my practice like abdominoplasties, Bonti’s EB-001 should undoubtedly help patients recover from abdominal wall surgery more quickly, better and with less opioids,” said Dr. Alan Matarasso, a renowned aesthetic plastic surgeon and currently a Bonti Medical Advisor. “I’m enthused by this novel neurotoxin’s target profile to significantly relieve pain by rapidly relaxing muscles and by reducing incisional tension allowing patients to potentially recover faster and be more satisfied.”

About Dr. Alan Matarasso

Dr. Matarasso is a native of Westchester County in New York, has a preeminent clinical practice in Manhattan, New York, achieved the rank of Clinical Professor of Plastic Surgery at Albert Einstein College of Medicine and is currently Clinical Professor of Surgery at Hofstra-Northwell University College of Medicine. He has devoted his career to the specialty of clinical and academic aesthetic plastic surgery. His dedication to medical training, education, and scientific research are manifested in his membership and active participation in more than twenty regional and national medical organizations including the prestigious American Association of Plastic Surgeons (AAPS), the American Society of Plastic Surgeons (ASPS), the American Society for Aesthetic Plastic Surgery (ASAPS) the American College of Surgeons (ACS) and the American Medical Association (AMA). Dr. Matarasso has published more than 300 research articles, reviews, editorials, posters, book chapters and journal supplements and lectured at more than 500 professional symposia on a broad variety of subjects. A prominent source to both print and broadcast journalists, he is often quoted in national newspapers and magazines and has been featured on all major TV networks and numerous radio broadcasts.

About EB-001

Bonti’s lead product candidate, EB-001, is an investigational botulinum neurotoxin serotype E (BoNT/E). EB-001 has a mechanism of action similar to the marketed BoNT/A products though it has a differentiated clinical profile. EB-001 has a fast onset of action (about 24 hours) and short duration of effect (about 4 weeks). Currently marketed BoNT/A products have an onset of action around 3-7 days and a duration of effect around 3-4 months. The unique target clinical profile of EB-001 is well suited for a vast range of aesthetic and therapeutic uses, including for the treatment of post-surgical and non-surgical musculoskeletal pain, with currently unmet needs.
About Bonti

Bonti, based in Newport Beach, California, is a rapidly emerging biotechnology company founded by world class neurotoxin experts with proven success at Allergan, one of the Fortune 500 fastest growing pharma companies. This team, with unsurpassed neurotoxin, aesthetic and pain expertise, is uniquely qualified to develop unprecedented treatment paradigms driven by a novel neurotoxin platform to become an innovative leader in both aesthetic and therapeutic markets. By turning the science of neurotoxins into beneficial patient and healthcare provider solutions, Bonti will improve lives by successfully addressing key unmet needs in markets with multi-billion dollar addressable opportunities.

For more information, please visit http://bonti.com.

Contact
Orlando Rodrigues
Media Relations
orlando@bonti.com
760.212.5727